The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Low high-density lipoprotein cholesterol (HDL-C) levels are linked to increased cardiovascular event risk.
• HDL possesses anti-atherogenic properties, including anti-inflammatory, anti-oxidative activities, and reverse cholesterol transport.
• Augmenting HDL-C levels may promote atherosclerotic plaque regression.

Purpose of the Study:

• To review the beneficial effects of HDL and detrimental effects of other lipoproteins in atherosclerosis.
• To describe the therapeutic effects of nicotinic acid in raising HDL-C levels.
• To evaluate the impact of HDL-C-raising therapies on cardiovascular events.

Main Methods:

• Literature review focusing on HDL-C, dyslipidemia management, and atherosclerosis.
• Analysis of studies investigating the role of HDL in plaque modification.
• Examination of clinical trial data on nicotinic acid monotherapy and combination therapy.

Main Results:

• HDL exhibits significant anti-atherogenic actions, including reverse cholesterol transport.
• Nicotinic acid effectively raises HDL-C levels.
• Nicotinic acid therapy, alone or combined, halts plaque progression and reduces cardiovascular events.

Conclusions:

• HDL-C is a critical target for cardiovascular disease management.
• Nicotinic acid is a valuable therapeutic agent for increasing HDL-C and mitigating cardiovascular risk.
• Further research into HDL-C-centric therapies holds promise for preventing atherosclerotic events.